The problem of choice of therapy for a patient with dorsalgia

Musculoskeletal pain syndromes are one of the most common causes of temporary disability, they are often associated with a significant decrease in the quality of life of patients. Due to the peculiarities of biomechanics (significant phy­sical exertion experienced throughout life, a large volume of movements in various directions), the lumbar spine is especially vulnerable, the lesion of which is often associated with the development of lumbar pain (PB). The mechanisms of formation of PB are diverse, however, as a rule, inflammation is the basis of the pain syndrome. The results of modern studies have convincingly demonstrated the presence of imaging and biochemical markers of the inflammatory process in the area of altered spinal structures, in particular, in intervertebral discs and arch-process joints. There are reasons to believe that it is the focus of inflammation that can be the source of pain, although in the future the role of the active inflammatory process may become less important, and other mechanisms are involved in maintaining pain and other clinical manifestations. In this regard, drugs should be chosen for the treatment of patients with PB, depending on the predominant action - analgesic or anti-inflammatory. In the article, along with the main mechanisms of the occurrence and persistence of PB, modern approaches to the treatment of such patients are considered. The undoubted validity of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of patients with PB is noted. Their most significant clinical effects are noted, which may be useful in the treatment of patients with PB. The features of side effects associated with the use of NSAIDs, including those from the gastrointestinal tract and the cardiovascu­lar system, are considered. Information is provided on the results of studies devoted to the study of the efficacy and safety of dexketoprofen (Dexonal®, Binnopharm Group) in the treatment of patients with PB. The undoubted positive properties of the drug are noted (rapid development of action with a powerful analgesic effect and a favorable safety profile) Dexonal®.

1. de Luca K., Tavares P., Yang H. et al. Spinal pain, chronic health conditions and health behaviors: Data from the 2016—2018 National Health Interview Survey. Int J Environ Res Public Health 2023;20(7):5369. DOI: 10.3390/ijerph20075369

2. Bigio J., MacLean E., Vasquez N. et al. Most common reasons for primary care visits in low- and middle-income countries: A systematic review. PLOS Glob Public Health 2022;2(5):e0000196. DOI: 10.1371/journal.pgph.0000196

3. Montgomery W., Sato M., Nagasaka Y., Vietri J. The economic and humanistic costs of chronic lower back pain in Japan. Clinicoecon Outcomes Res 2017;9(3):361-71. DOI: 10.2147/CEOR.S134130

4. Zemedikun D., Kigozi J., Wynne-Jones G. et al. Methodological considerations in the assessment of direct and indirect costs of back pain: A systematic scoping review. PLoS One 2021;16(5):e0251406. DOI: 10.1371/journal.pone.0251406

5. de Luca K., McLachlan A., Maher C., Machado G. Australian emergency department care for older adults diagnosed with low back pain of lumbar spine origin: a retrospective analysis of electronic medical record system data (2016-2019). BMC Emerg Med 2023;23(1):17. DOI: 10.1186/s12873-023-00789-8

6. Yabe Y., Hagiwara Y., Sugawara Y., Tsuji I. Association between low back pain and functional disability in the elderly people: a 4-year longitudinal study after the great East Japan earthquake. BMC Geriatr 2023;23(1):86. DOI: 10.1186/s12877-022-03715-y

7. Tsuji T., Matsudaira K., Sato H. et al. Association between presen-teeism and health-related quality of life among Japanese adults with chronic lower back pain: a retrospective observational study. BMJ Open 2018;8(6):e021160. DOI: 10.1136/bmjopen-2017-021160

8. Chen N., Fong D., Wong J. Health and economic outcomes associated with musculoskeletal disorders attributable to high body mass index in 192 countries and territories in 2019. JAMA Netw Open 2023;6(1):e2250674. DOI: 10.1001/jamanetworkopen.2022.50674

9. Sayed D., Grider J., Strand N. et al. The American Society of Pain and Neuroscience (ASPN) evidence-based clinical guideline of interventional treatments for low back pain. J Pain Res 2022;15:3729-832. DOI: 10.2147/JPR.S386879

10. Isaikin A.I., Akarachkova E.S., Isaikina O.Yu. et al. Back pain. Clinical guidelines. SPb: Scyfia-print; M.: Profmedpress, 2021. (In Russ.).

11. Hoy D., March L., Brooks P. et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73(8):968-74. DOI: 10.1136/annrheumdis-2013-204344

12. Park P., Dryer R., Hegeman-Dingle R. et al. Cost burden of chronic pain patients in a large integrated delivery system in the United States. Pain Pract 2016;16(8):1001-11. DOI: 10.1111/papr.12357

13. Katz J. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. J Bone Joint Surg Am 2006;88(2):21-8. DOI: 10.2106/JBJS.E.01273

14. van der Graaf J., Kroeze R., Buckens C. et al. MRI image features with an evident relation to low back pain: a narrative review. Eur Spine J 2023 Mar 9. DOI: 10.1007/s00586-023-07602-x

15. Regev G., Treister R., Brill S. et al. Low back pain patients' perceptions regarding their own radiology reports: Pre-intervention survey. J Pain Res 2023;16:933-41. DOI: 10.2147/JPR.S396844

16. Mafi J., McCarthy E., Davis R., Landon B. Worsening trends in the management and treatment of back pain. JAMA Internl Med 2013;173(17):1573-81. DOI: 10.1001/jamainternmed.2013.8992

17. Gusev E.I., Nikiforov A.S., Kamchatnov P.R. Neurological symptoms, syndromes and diseases. 2nd ed. M.: Geotar-Medica, 2014. (In Russ.).

18. Calvo E., Palacios I., Delgado E. et al. Histopathological correlation of cartilage swelling detected by magnetic resonance imaging in early experimental osteoarthritis. Osteoarthritis Cartilage 2004;12(11):878-86. DOI: 10.1016/j.joca.2004.07.007

19. Permuy M., Guede D., Lopez-Pena M. et al. Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits. BMC Musculoskelet Disord 2015;16:120-6. DOI: 10.1186/s12891-015-0572-8

20. Dedrick D., Goldstein S., Brandt K. et al. A longitudinal study of subchondral plate and trabecular bone in cruciate-deficient dogs with osteoarthritis followed up for 54 months. Arthritis Rheum 1993;36(10):1460-7. DOI: 10.1002/art.1780361019

21. Bai R., Li Y., Zhang F. Osteopontin, a bridge links osteoarthritis and osteoporosis. Front Endocrinol (Lausanne) 2022;13:1012508. DOI: 10.3389/fendo.2022.1012508 

22. Novikova A.V., Pravdyuk N.G., Saklakova V.S. et al. Degenerative disc disease in young people: cytokine profile and angiogenesis factors. Vestnik RGMU = Bulletin of the RSMU 2021;6:80-7. (In Russ.). DOI: 10.24075/brsmu.2021.061

23. Gjesdal S., Holmaas T., Monstad K., Hetkevik O. New episodes of musculoskeletal conditions among employed people in Norway, sickness sertification and return to work: a multi-registered cohort study from primary care. BMJ Open 2018;8(3):34-40. DOI: 10.1136/bmjopen-2017-017543

24. Nordeman L., Thorselius L., Gunnarsson R., Mannerkorpi K. Predictors for future activity limitation in women with chronic low back pain consulting primary care: a 2-year prospective longitudinal cohort study. BMJ Open 2017;7:e013974. DOI: 10.1136/bmjopen-2016-013974

25. Каратеев А.Е., Лила А.М., Дыдыкина И.С. и др. Персонификация применения нестероидных противовоспалительных препаратов при скелетно-мышечных заболеваниях. Резолюция по результатам совещания экспертов от 13 декабря 2017 г. Медицинский совет 2018;18:76-84. DOI: 10.21518/2079-701X-2018-18-76-84 Karateev A.E., Lila A.M., Dydykina I.S. et al. Personalization of the use of non-steroidal anti-inflammatory drugs for musculoskeletal diseases. Resolution on the results of the Meeting of Experts of December 13, 2017. Medicinskij sovet 2018 = Medical advice 2018;18:76-84. (In Russ.). DOI: 10.21518/2079-701X-2018-18-76-84

26. Kamchatnov P.R. Improving the efficiency and safety of treatment of patients with lumbar pain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2016;116(10):28-33. (In Russ.). DOI:10.17116/jnevro201611610128-33

27. Mauleon D., Artigas R., GarcHa M.L., Carganico G. Preclinical and clinical development of dexketoprofen. Drugs 1996;52(Suppl. 5):24-45. DOI: 10.2165/00003495-199600525-00005

28. Cabre F., Fernandez M., Calvo L. et al. Analgesic, antiinflammatory, and antipyretic effects of S(+)-ketoprofen in vivo. J Clin Pharmacol 1998;38(Suppl. 12):3S-10S. PMID: 9882076

29. Carne X., Rios J., Torres F. Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care. Methods Find Exp Clin Pharmacol 2009;31(8):533-40. DOI: 10.1358/mf.2009.31.8.1419070

30. Yazar M., Inan N., Ceyhan A. et al. Postoperative analgesic efficacy of intravenous dexketoprofen in lumbar disc surgery. J Neurosurg Anesthesiol 2011;23(3):193-7. DOI: 10.1097/ANA.0b013e31827464af

31. Moore R.A., Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol 2008;8:11. DOI: 10.1186/1472-6904-8-11

32. Beltran J., Martm-Mola E., Figueroa M. et al. Comparison of Dexketoprofen trometamol and ketoprofen in the treatment of osteoarthritis of the knee. J Clin Pharmacol 1998;38(S1):74S-80S. PMID: 9882085

33. Capriai A., Mas M., Bertoloti M. et al. Intramuscular dexketoprofen trometamol in acute lower back pain. 10th World Congress on Pain, IASP, California, 2002. Pp. 108-12.

34. Metscher B., Kubler U., Jahnel-Kracht H. [Dexketoprofen- trometamol and tramadol in acute lumbago]. Fortschr Med Orig 2001;118(4):147-51. (In German). PMID: 11217678

35. Calm R., Frohling M., Rittmeister M., Schmitt E. Sacroiliac joint dysfunction in patients with imaging-proven lumbar disc herniation. Eur Spine J 1998;7(6):450-3. DOI: 10.1007/s005860050107

36. Podchufarova E.V. Experience of using dexalgin in the treatment of acute musculoskeletal pain syndromes. E'ffektivnaya farmakoterapiya. Nevrologiya i Psihiatriya = Effective pharmacotherapy. Neurology and psychiatry 2012;(2):34-9. (In Russ).

37. Solovyeva E.Yu., Karneev A.N., Fedin A.I. Combined use of dexalgin and nimesil in the acute stage of dorsopathy. Vrach = Doctor 2007;(3):67-71. [In Russ.].

38. Merkulov Yu.A., Merkulova D.M., Kryzhanovsky G.N. The effectiveness of dexalgin on vertebrogenic and non-vertebrogenic dysregulation mechanisms in back pain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. = S.S. Korsakov Journal of Neurology and Psychiatry 2006;106(5):20-4. (In Russ.).

39. Pilipovich A.A. Dexketoprofen: therapeutic potential in neurology. Consilium Medicum 2018;20(9):71-5. (In Russ.). DOI: 10.26442/2075-1753_2018.9.71-75